Loss of tau function (as in disease states) selectively destabilizes the labile microtubule population, disrupting axonal transport while sparing stable domains
Prediction: Tau-targeted interventions will selectively impair transport of organelles requiring labile microtubules (mitochondria, endosomes) while sparing lysosome transport
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["MAPT/Tau Protein Microtubule Stabilizer"]
B["CDK5/GSK3B Activation Kinase Dysregulation"]
C["Tau Hyperphosphorylation Ser396/Thr231/Ser202"]
D["Tau Detachment Microtubule Destabilized"]
E["Tau Oligomers Paired Helical Filaments"]
F["Neurofibrillary Tangles Intraneuronal Inclusions"]
G["Axonal Transport Failure Synaptic Dysfunction"]
H["Neurodegeneration Tauopathy Spread"]
A --> B
B --> C
C --> D
D --> E
E --> F
D --> G
G --> H
F --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations5 with PMID5 mediumValidation: 0%6 supporting / 0 opposing
✓For(6)
5
No opposing evidence
(0)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
1
2
2
1
MECH 1CLIN 2GENE 2EPID 1
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
MAPT mutations, tauopathy, and mechanisms of neuro…
Loss of tau function (as in disease states) select…
Supporting
EPID
-
-
-
-
-
-
Legacy Card View — expandable citation cards
✓ Supporting Evidence
6
Loss of tau function (as in disease states) selectively destabilizes the labile microtubule population, disrup…▼
Loss of tau function (as in disease states) selectively destabilizes the labile microtubule population, disrupting axonal transport while sparing stable domains
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.MEDIUM
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Evaluation: Tau and MAP6 Establish Labile and Stable Domains on Microtubules
Key Scientific Contributions
1. Paradigm Shift: MAPs Create Rather Than Recognize Microtubule Domains
The paper's central finding challenges the prevailing view that MAPs passively bind to pre-existing stable or labile microtubule domains. Instead, tau and MAP6 actively establish these functional domains. This fundamentally reconceptualizes how the axonal cytoskeleton is organized—microtubule dynamics are not a pre-determined structural feature but are actively sculpted by MAP interactions.
2. Demo
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation: Tau and MAP6 Establish Labile and Stable Domains on Microtubules
Methodological Weaknesses
1. Non-Physiological Cell Model
The mechanistic evidence primarily derives from RFL-6 fibroblasts ectopically expressing fluorescent tau and MAP6. Fibroblasts lack neurons' specialized microtubule architecture (no axon initial segment, no organelle transport machinery, different tubulin isotype expression). Ectopic overexpression also bypasses endogenous regulatory mechanisms—transport to specific microtubule subpopulations, activity-dependent modulation, and cell-type
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Expert Assessment: Tau and MAP6 Establish Labile and Stable Domains on Microtubules
1. Novelty Rating: 7/10
The paper's core claim—that MAPs actively establish functional microtubule domains rather than passively binding to pre-existing ones—represents a meaningful conceptual advance. This paradigm shift moves beyond the prevailing "recognition" model in cytoskeletal biology. However, the novelty is tempered by:
Extensive prior literature on MAP-microtubule interactions (tau studied since the 1970s)
MAP6's known stability-promoting functions already established
The fundamenta
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"summary":"This paper demonstrates that tau and MAP6 actively establish rather than merely bind to labile and stable domains on microtubules. Using RFL-6 fibroblasts ectopically expressing fluorescent MAPs, the authors show that tau-rich domains become more labile while MAP6-rich domains become more stable, with these MAPs segregating to distinct domains on either different microtubules or different regions of the same microtubule. Computational modeling validates this mechanistic framework, while corroborative data from both juvenile and adult rodent axons confirms the in vivo relevance of t
IF CRISPR/Cas9-mediated MAPT knockout is performed in human iPSC-derived cortical neurons, THEN the mean anterograde velocity of mitochondria in distal axons will decrease by at least 40% relative to wild-type controls within 10 days, while the velocity of lysosomes will not change by more than 15%.
pendingconf: 0.60
Expected outcome: Selective ≥40% decrease in mitochondrial transport without significant change in lysosome transport.
Falsified by: If both mitochondrial and lysosome transport are reduced by ≥30% or if mitochondrial transport reduction is <30%, the hypothesis of selective destabilization of labile microtubules is falsified.
Method: CRISPR/Cas9 editing of MAPT in iPSC-derived cortical neurons; live-cell imaging of axonal transport using MitoTracker and Lysotracker; quantification of transport parameters over 10 days post-editing.
IF a selective labile microtubule stabilizer (e.g., 10 nM epothilone D) is applied to MAPT knockout neurons, THEN the mitochondrial transport deficit will be rescued to ≥80% of wild-type velocity within 48 h of treatment.
pendingconf: 0.55
Expected outcome: Restoration of mitochondrial transport velocity to ≥80% of wild-type levels after epothilone D.
Falsified by: If mitochondrial transport remains <50% of wild-type after 48 h of epothilone D treatment, the hypothesis that labile microtubule destabilization underlies the transport deficit is falsified.
Method: MAPT knockout iPSC-derived cortical neurons treated with 10 nM epothilone D; live-cell imaging of axonal mitochondria before and 48 h after drug addition; quantification of transport velocity.